Essential Partners
ANIP icon

Essential Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Essential Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$218 Hold
3
– – ﹤0.01% 2579
2026
Q2 		$248 Hold
3
– – ﹤0.01% 2603
2026
Q1 		$231 Hold
3
– – ﹤0.01% 2582
2025
Q4 		$237 Hold
3
– – ﹤0.01% 2398
2025
Q3 		$275 Hold
3
– – ﹤0.01% 2341
2025
Q2 		$196 Buy
+3
New +$195 ﹤0.01% 1949

Other funds holding ANIP

Oliver Luxxe Assets
Oliver Luxxe Assets Gladstone, New Jersey $638M AUM 30.27% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Polaris Capital Management
Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Quadrant Capital Group
Quadrant Capital Group Cincinnati, Ohio $3.7B AUM 33.76% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Essential Partners's ANIP Position: Q3 2026 in Review

Essential Partners held its ANI Pharmaceuticals (ANIP) position steady in Q3 2026 at 3 shares worth $218. The position accounts for ﹤0.01% of the portfolio, ranked #2579.

Essential Partners first reported a position in ANIP in Q2 2025 and has held it in 6 quarters since. The position peaked at $275 in Q3 2025. 24 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Essential Partners held 3 shares of ANI Pharmaceuticals worth $218 as of Q3 2026.
  • Essential Partners left its ANI Pharmaceuticals share count unchanged in Q3 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2579 holding.
  • Essential Partners first reported a position in ANI Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's ANI Pharmaceuticals position peaked at $275 in Q3 2025.
  • 24 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.